Abstract
The authors assessed CSF and plasma HIV-1 RNA and neuropsychological test performance (composite neuropsychological test Z score [NPZ-4]) in 25 HIV-1-infected subjects 4 and 8 weeks after beginning potent antiretroviral therapy that included a protease inhibitor. In the 14 subjects who entered the study on no antiretroviral treatment, NPZ-4 improvement was associated with decline in CSF HIV-1 RNA at both visits (p = 0.001 and p = 0.02), and those treated with zidovudine or indinavir had greater improvement in NPZ-4 at both visits compared to those treated with other drugs (p = 0.003 and p = 0.01).
Publication types
-
Comparative Study
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Anti-HIV Agents / therapeutic use*
-
Antiretroviral Therapy, Highly Active
-
Cognition Disorders / blood
-
Cognition Disorders / cerebrospinal fluid
-
Cognition Disorders / etiology
-
Cognition Disorders / virology
-
HIV Infections / drug therapy*
-
HIV Infections / psychology
-
HIV Infections / virology
-
HIV Protease Inhibitors / therapeutic use*
-
HIV-1 / isolation & purification*
-
Humans
-
Indinavir / blood
-
Indinavir / cerebrospinal fluid
-
Indinavir / therapeutic use
-
Male
-
Middle Aged
-
Neuropsychological Tests
-
RNA, Viral / blood
-
RNA, Viral / cerebrospinal fluid*
-
Time Factors
-
Viral Load
-
Viremia / drug therapy*
-
Viremia / psychology
-
Zidovudine / therapeutic use
Substances
-
Anti-HIV Agents
-
HIV Protease Inhibitors
-
RNA, Viral
-
Zidovudine
-
Indinavir